JA
JANX.US Janux Therapeutics Inc
- Market cap
- USD 696M
- P/E
- -
- P/B
- 0.76x
- ROE
- -9.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is JANX.US undervalued?
Graham numberThe Graham number of Janux Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Janux Therapeutics Inc fundamental analysis
No fundamental analysis for Janux Therapeutics Inc yet.
Janux Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-res…
Full company profileJanux Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Janux Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 380K | 3.64M | 8.61M | 8.08M | 10.6M | 10.0M | 31.1M |
| Gross Profit | -6.00K | -13.0K | 3.64M | 8.61M | 6.13M | 8.53M | 7.97M | 31.1M |
| Operating Income | -3.77M | -4.84M | -32.9M | -67.1M | -73.0M | -98.8M | -158M | -130M |
| EBITDA | -3.77M | -6.57M | -32.8M | -66.3M | -56.3M | -66.9M | -112M | -88.7M |
| Net Income | -4.24M | -6.78M | -32.6M | -54.2M | -58.3M | -69.0M | -114M | -90.5M |
| EPS | -0.10 | -0.16 | -0.79 | -1.31 | -1.32 | -1.28 | -1.83 | -1.44 |
| Balance Sheet | ||||||||
| Total Assets | 679K | 16.2M | 380M | 364M | 380M | 1.06B | 1.00B | 984M |
| Total Liabilities | 8.62M | 30.9M | 13.5M | 43.3M | 36.1M | 38.7M | 44.7M | 72.0M |
| Shareholders' Equity | -7.94M | -14.6M | 366M | 321M | 344M | 1.02B | 957M | 912M |
| Cash & Short-term Investments | 658K | 7.81M | 375M | 327M | 344M | 1.03B | 967M | 946M |
| Total Debt | 4.00M | - | 194K | 25.3M | 24.5M | 23.0M | 22.1M | 20.4M |
| Cash Flow | ||||||||
| Operating Cash Flow | -3.83M | -4.37M | -17.0M | -42.9M | -50.6M | -43.8M | -82.2M | -33.4M |
| Capital Expenditure | 1.48M | 1.48M | 1.48M | 6.45M | 1.85M | 359K | 1.04M | 636K |
| Free Cash Flow | -3.83M | -4.37M | -18.5M | -49.4M | -52.4M | -44.2M | -83.3M | -34.0M |
| Ratios | ||||||||
| ROE | - | - | -8.9% | -16.9% | -16.9% | -6.7% | -11.9% | -9.9% |
| ROA | -624.0% | -41.8% | -8.6% | -14.9% | -15.3% | -6.5% | -11.3% | -9.2% |
| Net Profit Margin | - | -1,785.3% | -895.2% | -628.8% | -721.2% | -651.6% | -1,136.3% | -291.6% |
| Debt to Equity | - | - | 0.00x | 0.08x | 0.07x | 0.02x | 0.02x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Janux Therapeutics Inc dividends
Janux Therapeutics Inc has not paid dividends in the last 7 fiscal years.
Who owns Janux Therapeutics Inc
- Insiders 1.26%
- Institutions 98.74%
- Public & others 0.00%
- Shares outstanding 61.2M
- Free float 46.4M
Top funds holding JANX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.55M | 2.54% | +22.93% | Sep 2026 |
| Federated Hermes MDT Small Cap Core IS | 1.37M | 2.25% | +6.95% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.22M | 1.99% | +2.69% | Oct 2026 |
| iShares Russell 2000 ETF | 1.21M | 1.98% | 0.00% | Oct 2026 |
| Bridge Builder Small Cap Fund | 569K | 0.93% | +61.74% | Oct 2026 |
| Nuveen Quant Small Cap Equity R6 | 541K | 0.88% | +1.62% | Sep 2026 |
| Vanguard Strategic Equity Inv | 496K | 0.81% | +16.98% | Sep 2026 |
| Fidelity Small Cap Index | 471K | 0.77% | 0.00% | Aug 2026 |
| iShares Biotechnology ETF | 451K | 0.74% | -0.19% | Oct 2026 |
| iShares Russell 2000 Value ETF | 451K | 0.74% | 0.00% | Oct 2026 |
| Federated Hermes MDT Small Cap Growth IS | 376K | 0.62% | 0.00% | Sep 2026 |
| BlackRock Advantage Small Cap Core Instl | 370K | 0.61% | +8.61% | Sep 2026 |
| Vanguard Explorer Inv | 326K | 0.53% | 0.00% | Sep 2026 |
| Fidelity Advisor Biotechnology I | 320K | 0.52% | 0.00% | Sep 2026 |
| Fidelity Series Small Cap Core | 318K | 0.52% | -3.11% | Aug 2026 |
| North Square Dynamic Small Cap I | 282K | 0.46% | +158.94% | Jun 2026 |
| Vanguard Russell 2000 ETF | 278K | 0.45% | +11.86% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 266K | 0.44% | +0.23% | Oct 2026 |
| Federated Hermes MDT Small Cap Core ETF | 250K | 0.41% | -2.44% | Oct 2026 |
| Fidelity Extended Market Index | 239K | 0.39% | -5.20% | Sep 2026 |
Top institutions holding JANX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, LLC | 11.2M | 18.29% | 0.00% | Jun 2026 |
| BlackRock Inc | 6.13M | 10.03% | +12.91% | Jun 2026 |
| Prosight Management, LP | 3.80M | 6.22% | +7.17% | Jun 2026 |
| State Street Corp | 3.00M | 4.91% | +21.95% | Jun 2026 |
| FMR Inc | 2.41M | 3.94% | -4.85% | Jun 2026 |
| Federated Hermes Inc | 2.35M | 3.85% | +4,241.19% | Jun 2026 |
| Point72 Asset Management, L.P. | 1.99M | 3.26% | +72.46% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.86M | 3.04% | +2.54% | Jun 2026 |
| TCG Crossover Management, LLC | 1.79M | 2.93% | 0.00% | Jun 2026 |
| Alyeska Investment Group, L.P. | 1.65M | 2.69% | +2.88% | Jun 2026 |
| Nantahala Capital Management, LLC | 1.62M | 2.65% | +100.00% | Jun 2026 |
| Wellington Management Company LLP | 1.51M | 2.46% | -5.65% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.33M | 2.18% | +3.14% | Jun 2026 |
| Two Sigma Investments LLC | 1.21M | 1.97% | +939.85% | Jun 2026 |
| Geode Capital Management, LLC | 1.20M | 1.97% | +5.01% | Jun 2026 |
| Citadel Advisors Llc | 1.20M | 1.96% | +240.95% | Jun 2026 |
| Algert Global LLC | 1.11M | 1.82% | +150.54% | Jun 2026 |
| D. E. Shaw & Co LP | 1.10M | 1.79% | +1,014.40% | Jun 2026 |
| The Goldman Sachs Group Inc | 953K | 1.56% | +58.25% | Jun 2026 |
| Bank of America Corp | 910K | 1.49% | +13.57% | Jun 2026 |
Janux Therapeutics Inc company profile
- Company name
- Janux Therapeutics Inc
- Ticker
- JANX.US
- Exchange
- USA Stocks
- Listed since
- Jun 11, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 114
- Fiscal year end
- December
- Address
- 10955 Vista Sorrento Parkway, San Diego, CA, United States, 92130
- Phone
- 858 751 4493
- Website
- januxrx.com
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Janux Therapeutics Inc management
7- Dr. David Alan Campbell Ph.D.President, Co-Founder, CEO & Director · born 1960
- Dr. Thomas Diraimondo Ph.D.Chief Scientific Officer · born 1986
- Ms. Janeen DoyleChief Corporate & Business Development Officer · born 1978
- Mr. Matt WhitmireVice President of Finance
- Ms. Maria DobekVice President of Accounting · born 1990
- Mr. James PenningtonGeneral Counsel & Corporate Secretary
- Ms. Mandie Forman-SklanskyHead of Human Resources